BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, ...
BeOne Medicines AG (formerly BeiGene, Ltd.) is a multinational oncology company founded in 2010 by John V. Oyler and Xiaodong Wang. Headquartered in Basel, Switzerland, with operations in the U.S., China, Europe, and internationally, it specializes in developing and commercializing cancer therapies. The company has a robust portfolio including commercial-stage ...BeOne Medicines AG (formerly BeiGene, Ltd.) is a multinational oncology company founded in 2010 by John V. Oyler and Xiaodong Wang. Headquartered in Basel, Switzerland, with operations in the U.S., China, Europe, and internationally, it specializes in developing and commercializing cancer therapies. The company has a robust portfolio including commercial-stage products like BRUKINSA (a BTK inhibitor for blood cancers), TEVIMBRA (an anti-PD-1 antibody), SYLVANT (for Castleman disease), and others. Its clinical pipeline includes novel treatments such as Sonrotoclax (Bcl-2 inhibitor), BGB-16673 (BTK degrader), and multiple antibody-drug conjugates (ADCs). Collaborations with major pharma like Amgen, BMS, and Novartis enhance its capabilities. Financially, the company has shown profitability with a net margin of 8.9%, revenue per share of $51.99, and a strong balance sheet with cash per share of $43.72. It employs around 12,000 people as of recent data, with a market cap of approximately $35 billion. The company is driven by a mission to transform cancer care and expand patient access globally. Under CEO John V. Oyler, BeOne continues to invest heavily in R&D (about 37.7% of revenue) while achieving operational efficiency.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$5.3B
+40.2%
+12.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$286.9M
+144.5%
+4.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+87.5%
+3.6%
+0.9%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+8.4%
+156.1%
+15.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
+5.4%
+131.7%
-7.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$941.7M
+240.6%
+270.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+17.6%
+200.3%
+228.5%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
45.9%
+41.5%
-8.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.41x
+89.1%
-6.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good day, everyone. Welcome to BeOne Medicines Q2 2026 Earnings Call Webcast. [Operator Instructions] At this time, I would like to turn the call over to the company.
Daniel Maller: Hello and welcome. Thank you for joining us today. I'm Dan Maller, Head of Investor Relations at BeOne Medicines. Before we begin, please note that you can find additional materials, including a replay of today's webcast and presentation on the Investor Relations section of our website, ir.beonemedicines.com. I would like to remind all participants that during this call, we may make forward-looking statements regarding, among other things, the company's future prospects and business strategy. Actual results may differ materially from those indicated in the forward-looking statements as a result of various factors, including those risks discussed in our most recent periodic report filed with the SEC. Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation. Reconciliations between GAAP and non-GAAP financial measures discussed on this call are provided in the appendix to our presentation, which is posted to our Investor Relations website, along with our earnings release. All information in this presentation is as of the date of this presentation, and we undertake no duty to update such information unless required by law. Now turning to today's call. As outlined on Slide 3, John Oyler, our Co-Founder, Chairman and CEO, will provide a business update. Aaron Rosenberg, our CFO, will provide an update on our second quarter financial results and 2026 financial guidance. And Lai Wang, President and Global Head of R&D, will discuss our R&D and pipeline progress. We will then open the call to questions. Joining the team for the Q&A portion of the call will be Dr. Wu, President and Chief Operating Officer; Matt Shaulis, General Manager of North America; Mark Lanasa, Chief Medical Officer for Solid Tumors; and Amit Agarwal, Chief Medical Officer for Hematology. I'll now pass the call over to John. John?
John Oyler: Thank you, Dan, and welcome, everyone. Q2 was a very strong quarter across every dimension of our business. From a financial perspective, we achieved $1.7 billion in total revenues and $2.05 in GAAP earnings per ADS. This represents growth of 30% and 144% compared to the prior year, respectively. BRUKINSA, our foundational BTK inhibitor continues to exceed our high expectations in the marketplace. More than 6.5 years after its initial launch, BRUKINSA is seeing its highest level of sustained new patient starts showing favorable early trends in duration of therapy, and it's showing strong growth across all five approved indications. On the back of these strong results, we're raising our 2026 guidance ranges for revenue and GAAP operating income by $300 million and $250 million, respectively, and Aaron will detail this later. As impressive as our financial performance was in the quarter, our …
